CN112040948A - 治疗瘙痒的组合物和方法 - Google Patents

治疗瘙痒的组合物和方法 Download PDF

Info

Publication number
CN112040948A
CN112040948A CN201980023503.1A CN201980023503A CN112040948A CN 112040948 A CN112040948 A CN 112040948A CN 201980023503 A CN201980023503 A CN 201980023503A CN 112040948 A CN112040948 A CN 112040948A
Authority
CN
China
Prior art keywords
sde
pharmaceutical composition
diisopropyl adipate
pharmaceutically acceptable
topical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980023503.1A
Other languages
English (en)
Chinese (zh)
Inventor
黄文英
李展荣
郭书玮
周志光
田宥恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Lumosa Therapeutics Co Ltd
Lumosa Therapeutics Co Ltd
Original Assignee
Shanghai Lumosa Therapeutics Co Ltd
Lumosa Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Lumosa Therapeutics Co Ltd, Lumosa Therapeutics Co Ltd filed Critical Shanghai Lumosa Therapeutics Co Ltd
Publication of CN112040948A publication Critical patent/CN112040948A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980023503.1A 2018-03-29 2019-03-28 治疗瘙痒的组合物和方法 Pending CN112040948A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650108P 2018-03-29 2018-03-29
US62/650,108 2018-03-29
PCT/US2019/024706 WO2019191511A1 (en) 2018-03-29 2019-03-28 Compositions and methods for treating pruritus

Publications (1)

Publication Number Publication Date
CN112040948A true CN112040948A (zh) 2020-12-04

Family

ID=68054657

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980023503.1A Pending CN112040948A (zh) 2018-03-29 2019-03-28 治疗瘙痒的组合物和方法

Country Status (13)

Country Link
US (2) US20190298702A1 (https=)
EP (1) EP3755328A4 (https=)
JP (1) JP2021525225A (https=)
KR (1) KR20200138730A (https=)
CN (1) CN112040948A (https=)
AU (1) AU2019243571A1 (https=)
BR (1) BR112020019094A2 (https=)
CA (1) CA3094710A1 (https=)
IL (1) IL277463A (https=)
MX (1) MX2020009813A (https=)
RU (1) RU2020130919A (https=)
TW (1) TWI729371B (https=)
WO (1) WO2019191511A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113797167B (zh) * 2020-06-16 2024-05-10 苏州恩华生物医药科技有限公司 一种塞纳布啡的储库制剂
CA3186630A1 (en) * 2020-06-30 2022-01-06 Dermira, Inc. Irak4 inhibitors and topical uses thereof
WO2022175973A1 (en) * 2021-02-18 2022-08-25 Navin Saxena Research And Technology Private Limited An injectable composition for long term delivery of nalbuphine or nalbuphine ester prodrug or its salts and use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
US6503944B1 (en) * 1999-05-26 2003-01-07 The Andrew Jergens Company Anhydrous skin care composition
US20030157138A1 (en) * 2000-01-10 2003-08-21 Meir Eini Dermatological application with solidified fat compositions
US20070093517A1 (en) * 2005-10-24 2007-04-26 Gary Newton Local anesthetic compositions
US20080069779A1 (en) * 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
CN106376232A (zh) * 2015-05-28 2017-02-01 顺天医药生技股份有限公司 用于持续释放癸二酰二纳布啡酯的药物制剂
CN106535897A (zh) * 2014-06-13 2017-03-22 特雷维治疗股份有限公司 用于治疗瘙痒的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130759C (https=) * 1965-10-07
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
ES2188481T3 (es) * 2000-04-27 2003-07-01 Oliver Yoa-Pu Hu Derivados de polinalbufina.
CA2788440A1 (en) * 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
EP2788028B1 (en) * 2011-12-08 2019-03-27 Rigel Pharmaceuticals, Inc. Topical formulation for administering a compound
US20140112957A1 (en) * 2012-10-19 2014-04-24 Oliver Yao-Pu Hu Analegisic (Sebacoyl dinalbuphine ester) PLGA controlled release formulation form

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
US6503944B1 (en) * 1999-05-26 2003-01-07 The Andrew Jergens Company Anhydrous skin care composition
US20030157138A1 (en) * 2000-01-10 2003-08-21 Meir Eini Dermatological application with solidified fat compositions
US20080069779A1 (en) * 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
US20070093517A1 (en) * 2005-10-24 2007-04-26 Gary Newton Local anesthetic compositions
CN106535897A (zh) * 2014-06-13 2017-03-22 特雷维治疗股份有限公司 用于治疗瘙痒的方法
CN106376232A (zh) * 2015-05-28 2017-02-01 顺天医药生技股份有限公司 用于持续释放癸二酰二纳布啡酯的药物制剂

Also Published As

Publication number Publication date
BR112020019094A2 (pt) 2020-12-29
US20220362226A1 (en) 2022-11-17
EP3755328A4 (en) 2021-11-10
WO2019191511A1 (en) 2019-10-03
IL277463A (en) 2020-11-30
JP2021525225A (ja) 2021-09-24
TW202002977A (zh) 2020-01-16
AU2019243571A1 (en) 2020-10-15
RU2020130919A3 (https=) 2022-04-29
KR20200138730A (ko) 2020-12-10
MX2020009813A (es) 2020-11-11
US20190298702A1 (en) 2019-10-03
TWI729371B (zh) 2021-06-01
RU2020130919A (ru) 2022-04-29
EP3755328A1 (en) 2020-12-30
CA3094710A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
US11517546B2 (en) High concentration local anesthetic formulations
EP2877155B1 (en) Opioid formulations
US12447146B2 (en) Topical composition comprising tacrolimus
KR20200128657A (ko) 토파시티닙을 포함하는 국소 제형
EP4091612B1 (en) Long-acting ropivacaine pharmaceutical composition, preparation method therefor and use thereof
US20220362226A1 (en) Compositions and methods for treating pruritus
KR20230004644A (ko) 약제학적 조성물
AU2019200982A1 (en) Opioid formulations
KR20230054682A (ko) Jak 저해제 및 라우레스-4를 함유하는 국소 제형
KR20210034615A (ko) 외용 제제
HK40036943A (en) Compositions and methods for treating pruritus
WO2017062837A1 (en) Treatment of skin disorders by topical administration of vegf inhibitors
JP2022515569A (ja) フェノルドパムの安定な局所用組成物
JP2007224022A (ja) ２２−オキサ−１α，２５−ジヒドロキシビタミンＤ３を含有する水中油型乳剤性ローション剤
WO2024245894A1 (en) (4r)-3-(4-fluoro-2-hydroxyphenyl)-4-methyl-4,5-dihydro-1h-pyrazole-1-carboximidamide hydrochloride and dermal formulations thereof
TW202519237A (zh) 用於治療痤瘡樣疹之皮甾酮-17α-丙酸酯
HK1161683A (en) Topical composition comprising a combination of at least two penetration enhancing agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40036943

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201204